TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06553261

Intervention type: PROCEDURE
Intervention: suturing of leak, lavage, drainage
Description: Operative suturing of the leak, lavage, drainage within a revision surgery.

Intervention type: PROCEDURE
Intervention: suturing of leak, lavage, drainage
Description: Operative suturing of the leak, lavage, drainage within a revision surgery.

Intervention type: PROCEDURE
Intervention: Formation of a new anasthomosis
Description: Operative resection of the old leaking anastomosis and formation of a new one.

Intervention type: PROCEDURE
Intervention: Formation of a new anasthomosis
Description: Operative resection of the old leaking anastomosis and formation of a new one.

Intervention type: PROCEDURE
Intervention: Fecal diversion
Description: Formation of a deviating stoma.

Intervention type: PROCEDURE
Intervention: Fecal diversion
Description: Formation of a deviating stoma.
Study: NCT04975945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone Sodium
Description: Intravenous vs local action

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone Sodium
Description: Intravenous vs local action
Study: NCT06307301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection [Orencia] and Proleukin (aldesleukin)
Description: Abatacept (Orencia®) and recombinant human IL-2 (aldesleukin). Patients will receive a fixed dose of subcutaneous abatacept (125 mg/mL) at day 1. Two weeks later (day 15), patients will receive the second dose of subcutaneous abatacept (125 mg/mL). In addition, patients will receive subcutaneous IL-2 (1x106units /day) for 5 days (days 15-19). If this treatment regimen is tolerated, patients will receive 28 further similar treatment courses of abatacept and IL-2 every two weeks.
Study: NCT05403567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bootle Blast Home Intervention
Description: Children will play BB at home for 8 continuous weeks. Participants will be asked to stop playing at the end of week 8 and the game will be programmatically locked to prevent further play until the post-intervention interviews and assessments are complete.
Study: NCT04811690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: front-of-package modification
Description: testing front-of-package changes to claims, imagery, disclosures, and added sugar warning labels on fruit-flavored drinks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: front-of-package modification
Description: testing front-of-package changes to claims, imagery, disclosures, and added sugar warning labels on fruit-flavored drinks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: front-of-package modification
Description: testing front-of-package changes to claims, imagery, disclosures, and added sugar warning labels on fruit-flavored drinks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: front-of-package modification
Description: testing front-of-package changes to claims, imagery, disclosures, and added sugar warning labels on fruit-flavored drinks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: front-of-package modification
Description: testing front-of-package changes to claims, imagery, disclosures, and added sugar warning labels on fruit-flavored drinks
Study: NCT05705388

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POSE2.0 Endoscopic Gastric Remodeling
Description: The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POSE2.0 Endoscopic Gastric Remodeling
Description: The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide injection
Description: Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide injection
Description: Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
Study: NCT04876911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated Presence Therapy
Description: A video recording of a loved one is played (via an iPad) prior to or during periods where a participant is presenting with stressed/distressed behaviours.
Study: NCT05197556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration
Study: NCT06143644

Intervention type: OTHER
Intervention: Serial ctDNA monitoring
Description: Baseline blood samples, surgical resected tumor tissue, blood samples after surgery (D5-7), blood samples before adjuvant therapy and blood samples after adjuvant therapy (every 3 months for up to 2 years follow-up) will be collected from colorectal patients.
Study: NCT05877391

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SGM Communication Intervention
Description: Evaluate the feasibility and acceptability of the SGM communication intervention by hospice staff. I will pilot test the training with hospice staff to refine the content and delivery of the training. Outcomes in the pilot clinical trial will include feasibility, acceptability, and staff satisfaction with training.
Study: NCT06217302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotagliflozin
Description: Oral sotagliflozin (200 mg per day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive tablets identical to sotagliflozin tablets
Study: NCT05230498

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anatomy-based fitting then default fitting
Description: Cochlear implant with anatomy-based fitting then default fitting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: default fitting then anatomy-based fitting
Description: Cochlear implant with anatomy-based fitting then default fitting
Study: NCT06268899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First mobilization protocol
Description: The protocol phases start one day before the patient's surgery and end on the first day of mobilization after surgery. The investigator explains the protocol steps to the patient before surgery and the patient is mobilized within the first 24 hours after surgery. Perform the protocol 4 times a day and more as tolerated. Mobilization protocol: Level 1: Patient is informed about mobilization and readiness is reinforced. Level 2: Passive and active ROM movements in bed should be performed at least 3 times a day. Level 3: Head of bed \>60 degrees when the patient is sitting in bed. Duration target: 10-15 minutes. Level 4: Patient is seated on the edge of the bed. Duration target: 10-15 minutes. Level 5: The patient is helped to stand up. Level 6: First mobilization is achieved by allowing the patient to take 10-15 steps. The patient can mobilize at least 4 times a day.
Study: NCT06447545

Intervention type: DEVICE
Group type: OTHER
Intervention: Changing pressure of Pneumoperitoneum to 6-10 mmHg
Description: Result of changing pneumoperitoneum pressure on CBD injury and pain

Intervention type: DEVICE
Group type: OTHER
Intervention: Changing pressure of Pneumoperitoneum to 12-15 mmHg
Description: Result of changing pneumoperitoneum pressure on CBD injury and pain
Study: NCT04831086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Drug
Description: Steroids doses will be optimized in the intervention group according the risk based on predictive models

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocolytic Agents
Description: Tocolysis duration will be optimized in the intervention group according the risk based on predictive models
Study: NCT04863417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 0.01% or vehicle Ointment QD applied to 2000 cm2 Body Surface Area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 0.01% or vehicle Ointment QD applied to 4000 cm2 Body Surface Area
Study: NCT05283889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genicular Radiofrequency Ablation
Description: After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Genicular Radiofrequency Ablation
Description: After the cannulae are placed and tines deployed, a single lesion (no electrical signal applied to patient) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
Study: NCT05949606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: Administration by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: Administration by intravenous infusion
Study: NCT02579187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tooth extraction
Description: The study tooth will be removed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tooth extraction
Description: The study tooth will be removed
Study: NCT05104099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvixia Topical Cream
Description: Metvixia is applied with a spatula, in a thick layer, to clinically visible lesions and all over the vulva. After applying the cream, the area will be covered with a bandage which should remain in place for 3 hours. After 3 hours of application, the bandage and the cream will be carefully removed. The application area will be cleaned and then immediately exposed to a continuous spectrum of light at a wavelength of 405 nm by a xenon lamp.~The most fluorescent areas will be identified. Then in white light, the practitioner will perform at least two biopsies under non-topical local anesthesia in the area of application of Metvixia®: one in the fluorescent area and one in the non-fluorescent area.~If there is no fluorescent labeling, two samples will be taken from two different non-fluorescent areas. In the event that all the zone is fluorescent , two samples will be taken from two different fluorescent zones.
Study: NCT05135728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unstuck and On Target: Preschool
Description: Unstuck \& On Target: Preschool (UOT:P) is a group-based curriculum for preschool and kindergarten students that targets executive function skills using CBT techniques. The UOT-P curriculum consists of 16 child small-group or classroom-wide lessons. Each lesson follows a clear structure in which the theme for the session is introduced in a storybook, supported with manipulatives and visuals. Children implement the skills introduced in the storybook through joing play activities that require them to flexibly adjusting their plans to work together. Children learn key vocabulary and active coping and problem-solving skills, with adult modeling and scaffolding, that enable them to build early executive functioning skills for self-regulation and classroom participation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstuck and On Target: Preschool
Description: Unstuck \& On Target: Preschool (UOT:P) is a group-based curriculum for preschool and kindergarten students that targets executive function skills using CBT techniques. The UOT-P curriculum consists of 16 child small-group or classroom-wide lessons. Each lesson follows a clear structure in which the theme for the session is introduced in a storybook, supported with manipulatives and visuals. Children implement the skills introduced in the storybook through joing play activities that require them to flexibly adjusting their plans to work together. Children learn key vocabulary and active coping and problem-solving skills, with adult modeling and scaffolding, that enable them to build early executive functioning skills for self-regulation and classroom participation.
Study: NCT05024552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Gilteritinib is an oral inhibitor of FLT3-ITD and FLT3-TKD. Dose cohort 1 will receive 120mg daily on days 6-19 of induction and days 4-17 of re-induction and consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Gilteritinib is an oral inhibitor of FLT3-ITD and FLT3-TKD. Dose cohort 1 will receive 120mg daily on days 6-19 of induction and days 4-17 of re-induction and consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: Vyxeos is a liposomal encapsulation of cytarabine and daunorubicin. It is given as an intravenous infusion over 90 minutes on days 1, 3 and 5 of induction and days 1 and 3 of re-induction and consolidation. The induction and reinduction dose is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion. The consolidation dose is 29mg/m2 daunorubicin and 65mg/m2 of cytarabine with each dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: Vyxeos is a liposomal encapsulation of cytarabine and daunorubicin. It is given as an intravenous infusion over 90 minutes on days 1, 3 and 5 of induction and days 1 and 3 of re-induction and consolidation. The induction and reinduction dose is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion. The consolidation dose is 29mg/m2 daunorubicin and 65mg/m2 of cytarabine with each dose.
Study: NCT06309667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-102(MG12)
Description: GLP-1 and GLP-2 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-102(MG12)
Description: GLP-1 and GLP-2 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-102(MG12)
Description: GLP-1 and GLP-2 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-102(MG12)
Description: GLP-1 and GLP-2 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-102(MG12)
Description: GLP-1 and GLP-2 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-102(MG12)
Description: GLP-1 and GLP-2 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-102(MG12)
Description: GLP-1 and GLP-2 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-102(MG12)
Description: GLP-1 and GLP-2 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-102(MG12)
Description: GLP-1 and GLP-2 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-102(MG12)
Description: GLP-1 and GLP-2 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-102(MG12)
Description: GLP-1 and GLP-2 fusion protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug of PG-102(MG12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug of PG-102(MG12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug of PG-102(MG12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug of PG-102(MG12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug of PG-102(MG12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug of PG-102(MG12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug of PG-102(MG12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug of PG-102(MG12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug of PG-102(MG12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug of PG-102(MG12)
Study: NCT04731311

Intervention type: DEVICE
Group type: OTHER
Intervention: Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease
Description: 4 participants with undergo 4 usability evaluations each, inter-spaced by days when researchers will address design changes. 2 participants will be elderly healthy and 2 will have the early Alzheimer's disease. Each session will last up to 1 hour, during which participants will interact with tasks in the form of games. Games will be gradated in level of difficulty, increasing from session to session. They will be played with one game controller or with two controllers while participants wear an all-in-one head mounted display. The degree of cognitive engagement during tasks will be measured with custom biosensors and used in adjusting level of difficulty. Each participant will fill subjective evaluation form and a USE form assessing ease of use, usefulness, and perceived technology issues. Scores will be analyzed and data published, in conjunction with game performance data.
Study: NCT06309667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug of PG-102(MG12)
Study: NCT05941273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smaller incision, new generation implantable miniature telescope (SING-IMT)
Description: The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
Study: NCT04719104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Bilirubin Meter - 'Bilimeter'
Description: Taking a transcutaneous (TcB) measurement will involve using a 'biliflash'. This is a non-invasive measurement that involves flashing a light against the helix of the infant's ear and can be done at the cotside. This process takes approximately 1-2 minutes and does not cause the baby discomfort. The meter gives an immediate bilirubin level.
Study: NCT05076045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal sound amplification products
Description: Participants will be tested with bilateral personal sound amplification products.
Study: NCT05910658

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Competence in Romance and Understanding Sexual Health (CRUSH)
Description: Manualized curriculum targeting sexual health and behavior in intimate relationships designed to meet the specific needs of autistic adults
Study: NCT05910047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Dietary supplement containing molecular hydrogen and pyrroloquinoline quinone

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert substance
Study: NCT06368401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Versa Implant
Description: The Versa Vascular Implant and Delivery System consists of a percutaneously delivered, permanent right-atrial implant and the delivery catheter that is used to first position the implant over the native valve orifice and to then place the implant.
Study: NCT05859178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Along with nerve transfer surgery, individuals in the exercise group will undergo handgrip exercise for 30 minutes a day, 5 days a week for a total of 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Along with nerve transfer surgery, individuals in the exercise group will undergo handgrip exercise for 30 minutes a day, 5 days a week for a total of 12 weeks.